ARKG
ETF
Genomics
NYSEARCA
ARK Genomic Revolution ETF
$42.57
-0.05 (-0.12%)
Fund Overview
by ARK Invest
Actively managed fund focused on the genomic revolution: gene editing (CRISPR), molecular diagnostics, targeted therapeutics, stem cells, and agricultural biology. High-conviction positions in companies reshaping medicine.
AUM$1.8B
Expense Ratio0.75%
Holdings35
Dividend Yield0.0%
DistributionAnnually
BenchmarkNone (Active)
InceptionOct 2014
ExchangeNYSEARCA
Price Data
Open$43.00
Prev Close$42.62
Day Range$42.46 — $43.91
52W Range$17.55 — $34.37
52-Week Range
$17.55
$34.37
From 52W High
23.9%
From 52W Low
+142.6%
Genomics ETF Comparison
Top Genomics Stocks
View all →
| Stock | Price | Change | Market Cap |
|---|---|---|---|
| ABBV | $254.76 | -2.42% | 461.26B |
| AMGN | $366.44 | -2.06% | 201.93B |
| GILD | $129.61 | -1.26% | 162.98B |
| VRTX | $529.59 | +0.29% | 131.79B |
| REGN | $649.81 | -0.68% | 68.59B |
| ALNY | $313.04 | +0.08% | 41.76B |
| RVMD | $189.99 | +0.40% | 40.23B |
| NTRA | $283.80 | +1.60% | 40.00B |
| BIIB | $208.46 | -3.54% | 31.91B |
| MRNA | $81.80 | +2.56% | 31.65B |
ARKG FAQ
What is ARKG?
ARKG is the ARK Genomic Revolution ETF, an exchange-traded fund managed by ARK Invest. It tracks the None (Active) and holds 35 Genomics securities with an expense ratio of 0.75%.
What is the expense ratio of ARKG?
ARKG charges an annual expense ratio of 0.75%, which means you pay $75.00 per year for every $10,000 invested. This fee is deducted automatically from the fund's returns.
Explore Genomics Stocks
View our full list of individual genomics stocks with prices, fundamentals, and analyst ratings.
Last updated: Jul 2, 2026 at 5:00 PM ET